Untitled

Abstract

This study aimed to assess the efficacy of intrauterine instillation of Autologous Blood Cell Derivative (ABCD-Endosera) in improving endometrial receptivity among infertile women with thin endometrium undergoing Frozen Embryo Transfer (FET). A total of 123 women were initially assessed for eligibility, and 23 of them did not meet the inclusion criteria and were excluded from the study. Eventually, 100 patients with thin endometrium (<7mm) and previously canceled fro-zen embryo transfer (FET) cycles were recruited. ABCD-Endosera was prepared by concentrating growth factors and anti-inflammatory cytokines from selectively enriched platelets derived from autologous blood. Three 0.8ml doses of ABCD-Endosera were administered into the uterine cavity using a Tomcat catheter. The first dose was given between days 5-7 of the menstrual cycle, the second dose followed five days later, and the third dose was given 48 hours prior to the embryo transfer. Following ABCD-Endosera treatment, the thickness of the endometrium significantly increased from an average of 6.43 ± 0.42 mm before treatment to 7.85 ± 0.27 mm (p < 0.05). Among these 00 women, 59% (59 patients) achieved pregnancy after receiving ABCD-Endosera treatment. Out of the pregnant women, 21% (21 patients) successfully delivered healthy fullterm babies, 20% (20 patients) had progressing pregnancies without complications, 10% (10 patients) experienced miscarriage before 10 weeks, and 8% (8 patients) had chemical pregnancies. No adverse effects, such as infection or anaphylaxis, were reported in any of the patients. This study highlights the significant potential of ABCD-Endosera as a promising solution to improve endometrial thickness, leading to better pregnancy outcomes for patients with persistently thin endometrium. Continued research is vital to fine-tune and maximize ABCD-Endosera's effectiveness in fertility procedures.